Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Etilefrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.71 |
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.68 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.68 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.68 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.68 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.68 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.68 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.68 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.68 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.68 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.68 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.68 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.68 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.45 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | GALR3 | O60755 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etilefrine SCHEMBL31204243 | 1.00 | HIF1A (0.97) | HIF1ALMNAGALR3KDM4EBLM | |
| Etilefrine SCHEMBL29603739 | 0.98 | HIF1A (1.00) | HIF1ALMNAGALR3KDM4EBLM | |
| Etilefrine SCHEMBL150802 | 0.98 | HIF1A (1.00) | HIF1ALMNAGALR3KDM4EBLM | |
| Etilefrine SCHEMBL30510958 | 0.98 | HIF1A (1.00) | HIF1ALMNAGALR3KDM4EBLM | |
| Etilefrine SCHEMBL2733170 | 0.87 | HIF1A (0.78) | HIF1ALMNAGALR3KDM4EBLM | |
| Etilefrine SCHEMBL5488709 | 0.87 | HIF1A (0.78) | HIF1ALMNAGALR3KDM4EBLM | |
| Etilefrine SCHEMBL10753730 | 0.87 | HIF1A (0.78) | HIF1ALMNAGALR3KDM4EBLM | |
| Phenylephrine SCHEMBL3643743 | 0.83 | HIF1A (1.00) | HIF1ALMNAGALR3KDM4EBLM | |
| Phenylephrine SCHEMBL5053821 | 0.83 | HIF1A (1.00) | HIF1ALMNAGALR3KDM4EBLM | |
| Phenylephrine SCHEMBL21829033 | 0.83 | HIF1A (1.00) | HIF1ALMNAGALR3KDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 694 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108956798-A | A kind of morphine hydrochloride preparation content determining method | 青海省药品检验检测院 | 2018-12-07 | — | — | CN | claimed |
| US-20140377328-A1 | INTRAORAL SOLUBLE-TYPE FILM PREPARATION | KYUKYU PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | claimed |
| US-20070148235-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | claimed |
| EP-0974366-B1 | ORAL PHARMACEUTICAL PREPARATIONS DECREASED IN BITTERNESS BY MASKING | EISAI CO LTD (JP) | 2006-10-18 | — | — | EP | claimed |
| US-20050152975-A1 | Pharmaceutical composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-07-14 | — | — | US | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| US-20040151688-A1 | Adhesive treatment for epistaxis | CLOSURE MEDICAL CORPORATION (US) | 2004-08-05 | — | — | US | claimed |
| US-6576677-B1 | Including polyvinylpyrrolidone and/or copolymer; suppressing precipitation or decomposition | EISAI CO., LTD. (JP) | 2003-06-10 | — | — | US | claimed |
| EP-1161956-A1 | MEDICINAL COMPOSITIONS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3747962-B1 | COATING COMPOSITION FOR APPLYING INKJET PRINTING THERETO TO FORM MARKED PREPARATION, PREPARATION MARKED WITH AQUEOUS INK, AND METHOD FOR PRODUCING MARKED PREPARATION | SHINETSU CHEMICAL CO (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | disclosed |
| EP-0145240-A2 | Method for producing Microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| EP-0103830-A2 | Phenylethylemine derivatires as growth stimulators | BAYER AG (DE) | 1984-03-28 | — | — | EP | disclosed |
| US-4193985-A | TIME-RELEASE, WEIGHTING AGENTS | A/S ALFRED BENZON (DK) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152975-A1 | Pharmaceutical composition | TAS2R5, TAS2R60, TAS2R16 | GAA 25/4885ADRB2 3119/4885ADRB1 3500/4885 |
| US-20070148235-A1 | PHARMACEUTICAL COMPOSITION | TAS2R5, TAS2R60, TAS2R16 | GAA 25/4885ADRB2 3119/4885ADRB1 3500/4885 |
| US-20040151688-A1 | Adhesive treatment for epistaxis | ICAM1, ELANE, EPCAM | GAA 3897/4885ADRB2 2948/4885ADRB1 3305/4885 |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | KCNN2, KCNN1, KIT | GAA 2470/4885ADRB2 2077/4885ADRB1 2562/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | GAA 608/4885ADRB2 3306/4885ADRB1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.